BioCentury | Dec 24, 2012
Company News
Sygnis Pharma diagnostic news
Sygnis said it will reduce headcount by 10 (30%) to 23 and discontinue its KIBRA R&D project. The company said it was not possible to out-license the project within the available timeline and the project...